Abstract
Pelvic endometriosis remains a difficult gynaecological problem to manage and yet the progression of the disease can be very detrimental to the health of the patients. Surgical treatment often involves removal of the reproductive as well as the hormonal functions of the patient. With the discovery of GnRH analogues ability to induce reversible suppression of the hypothalamic-pituitary-ovarian axis, it becomes possible to produce a hypoestrogenic state which allows regression of the disease. This paper reports on a Phase III clinical trial on the use of buserelin (Hoechst China Ltd) in the management of patients with severe pelvic endometriosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
